KAIST Researchers Unveil RNA-Based Therapeutic Strategy to Combat Cancer Cachexia

A research team at KAIST has identified a new therapeutic principle for cancer-associated cachexia, a debilitating condition causing muscle loss in cancer patients. The team developed an RNA-based strategy that blocks a specific brain signal, preventing muscle breakdown and potentially extending survival. This approach targets the GDF15 signaling protein and its receptor GFRAL in the brainstem, which normally instruct the body to break down muscle and fat. The therapy improved both muscle loss and metabolic dysfunction in studies, suggesting it could serve as a next-generation adjuvant therapy to enhance patient quality of life and treatment effectiveness.